Add ear gene therapy company Akouos to the ever-growing list of IPOs amid Covid-19

For investors looking to cash in on a burgeoning ear therapy space, the latest biotech angling for a public debut could be music to their ears.

Fresh off a $105 million raise in March, ear gene therapy company Akouos is looking for another $100 million for a chance to dance on the Nasdaq well before its lead product enters the clinic.